Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Steik Jason Paul, holds the title of Chief Clinical Officer at Pennant Group, Inc..
On 2026-11-17, the insider transacted 218 shares.The shares were transacted at a weighted average price of $37.15 per share, resulting in a total market-relevant value of $8K.
Steik Jason Paul (Chief Clinical Officer) sold $8K of $PNTG
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.